One of the challenges I face as a portfolio manager is handling the daily onslaught of data. It's like trying to drink water from a fire hose; you want to sip through a straw so you don't get your face ripped off. I'm constantly on the lookout for market data services that are better, faster and cheaper than the 30 or so sources I presently use.
I'd like to highlight several excellent and mostly free investment tools that I routinely use in my investing and money managing. Each tool offers a unique insight or presents data in a uniquely useful fashion.Ed Yardeni's Stock Market Valuation Calculator
An oft-debated topic is whether the stock market is over- or undervalued given current price-to-earnings
levels. As I discussed in Stock Market Valuations: Too High, Too Low or Just Right? last spring, the real question is whether the S&P 500 is overvalued given forward P/E levels and expected interest rates.
Ed Yardeni, the chief economist at Deutsche Banc Alex. Brown, built a MarketGuide's Ratio Comparison Report
Basic data on stocks are plentiful and free on the Web, but for detailed information I like MarketGuide. It was originally a very expensive non-Web product, then a $40/month Web product, and it's now a free product after merging with Multex. In particular, I use the ratio comparison report because it allows me in one screen to size up a company vs. its industry group, sector and the S&P 500 (note that to view a ratio comparison report, you'll need to register on the site first). Just enter a stock symbol, select "quote" and then select "ratio comparison" under "company information." If I were to do a ratio comparison of Johnson & Johnson(JNJ Quote), for example, I quickly see that JNJ is priced a little more richly than the average S&P 500 stock, reflecting the stability of its revenue and earnings growth. I also see that it's got a low beta and large operating margin, and is priced in line with its industry group. So no easy money to be made here, but no obvious risks either.Zacks Earnings Estimates (Company Report)
Zacks is one of two services that aggregate analysts' earnings estimates. As we all know by now, these estimates are less than perfect, given accounting problems and investment banking conflicts. However, there's still useful information in seeing how a company's prospects stack up relative to its peers and to the S&P 500. Zacks now makes these estimates available for free, summarized in the Company Report. Looking, for example, at the report for Wal-Mart (WMT Quote), if you skip down to the Company vs. Industry section, you'll see the following chart.| Zacks' Company Report on Wal-Mart |
Chuck Hill's Market Commentary at First Call
First Call is the other service that aggregates earnings estimates. Although access to its reports is by subscription only (note: you can get the same reports for free under the Research tab in Yahoo! Finance, the unique (and free) feature at First Call isMorningstar Instant X-Ray
A couple of years ago I wrote a column in which I described how to compile position data, sector allocations and risk factors such as beta
into an Excel spreadsheet to analyze the risk of your portfolio. For a portfolio containing 40 stock/mutual fund positions, though, this could take all day.
About a year ago, however, Morningstar came out with its Instant X-Ray tool, which lets you do the same analysis in a fraction of the time.
Just take your year-end statements, including both stocks and mutual funds, and type in the symbol and current dollar value. The X-Ray report summarizes your asset allocation, style diversification, sector allocation, stock types, portfolio aggregate P/E ratio, yield compared with the S&P 500 and percentage of your portfolio allocated to the top 10 holdings.
I actually use the premium version of the tool, which costs $11.95 a month, to analyze prospective client's portfolios, replacing a previous service that cost several hundred dollars a month. The premium version gives me all the above reports, plus other useful reports and statistics, and lets me save individual portfolios for subsequent review.




